AU2018229507B2 — Drug eluting ocular implant
Assigned to Glaukos Corp · Expires 2020-04-02 · 6y expired
What this patent protects
sxd\nterwovn\NRPortbl\DCC\SXD\8460760_l.docx-I6/09/2015 ABSTRACT Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or preventi…
USPTO Abstract
sxd\nterwovn\NRPortbl\DCC\SXD\8460760_l.docx-I6/09/2015 ABSTRACT Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device. 1/56 N N K1 N N N
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.